Plasma Cell Myeloma, Residual Disease
Conditions
Brief summary
This randomized phase II trial studies how well lenalidomide alone compared to lenalidomide, ixazomib citrate, and dexamethasone work in treating patients with multiple myeloma that remains (residual) after donor stem cell transplant. Lenalidomide may help the immune system kill abnormal blood cells or cancer cells and may also prevent the growth of new blood vessels that are needed for cancer growth. Ixazomib citrate may stop the growth of cancer cells by interfering with proteins necessary for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether lenalidomide is more effective with or without ixazomib citrate and dexamethasone in treating residual multiple myeloma.
Detailed description
PRIMARY OBJECTIVES: I. To determine the rate of minimal residual disease (MRD)-negative disease by multiparameter-flow cytometry at 12 months after randomization. SECONDARY OBJECTIVES: I. Evidence of response as demonstrated by the improvement of the depth of response by at least one category according to International Myeloma Working Group (IMWG) response criteria. II. Progression free survival (PFS). III. Overall survival (OS). IV. Duration of MRD-negative disease. V. Safety and tolerability of experimental arm (ixazomib citrate, lenalidomide, and low dose dexamethasone \[IRd\]) vs. control arm (lenalidomide \[Rd\]). TERTIARY OBJECTIVES: I. Determination of markers of response based on pre-treatment characteristics using methods described in correlative research. II. Evaluation of MRD by gene sequencing method using the Sequenta platform (LymphoSIGHT®) in parallel with multi-parameter flow cytometry (MFC). OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive ixazomib citrate orally (PO) on days 1, 8, and 15, lenalidomide PO once daily (QD) on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22 (of courses 1-4 only). ARM II: Patients receive lenalidomide PO as in Arm I. In both arms, treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. After the completion of treatment, patients are followed up at 30 days and then every 3 months for 2 years.
Interventions
DRUGIxazomib Citrate
Given PO
DRUGLenalidomide
Given PO
DRUGDexamethasone
Given PO
Sponsors
University of Chicago
National Cancer Institute (NCI)
Multiple Myeloma Research Foundation
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients who completed induction treatment followed by autologous stem cell transplant as initial therapy for symptomatic myeloma as per IMWG criteria and initiated Revlimid (lenalidomide) maintenance * Patients must have initiated lenalidomide maintenance at approximately 3 months post autologous stem transplant (preferably 70-90 but not more than 120 days) * Patients must be receiving lenalidomide 10 mg or 15 mg and be able to tolerate dose escalation to 25 mg daily * Patients must have received lenalidomide maintenance for 3 months (+1 month window for a maximum of 4 months lenalidomide prior to enrollment) * No evidence of progressive disease on lenalidomide * Any measurable residual disease at the time of screening for the study documented in at least one of the following ways: * Serum protein electrophoresis (SPEP)/immunofixation studies (IFIX) positive disease * Freelite only positive disease * SPEP/IFIX - negative and Freelite- negative but MRD-positive disease is allowed * Evidence of MRD at the time of screening for this study by multi-color flow cytometry (bone marrow procedure at screening required) * Bone marrow specimen will be required at study entry; available deoxyribonucleic acid (DNA) sample will be used for calibration step for MRD evaluation by gene sequencing * Life expectancy of more than 3 months * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Bilirubin =\<1.5 x upper limit of normal (ULN) * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 3 x ULN * Absolute neutrophil count (ANC) \>= 1.0 x 10\^9/L * Hemoglobin \>= 8 g/dL * Platelet count \>= 75 x 10\^9/L * Calculated creatinine clearance (by Cockroft-Gault) \>= 50 ml/min or serum creatinine below 2 g/dL * Voluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care * Female patients who: * Are postmenopausal for at least 1 year before the screening visit, OR * Are surgically sterile, OR * If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 90 days after the last dose of study drug, OR * Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence \[e.g., calendar, ovulation, symptothermal, post-ovulation methods\] and withdrawal are not acceptable methods of contraception) * Male patients, even if surgically sterilized (i.e., status post-vasectomy), must agree to one of the following: * Agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug, OR * Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence \[e.g., calendar, ovulation, symptothermal, post-ovulation methods\] and withdrawal are not acceptable methods of contraception)
Exclusion criteria
* Evidence of progressive disease on lenalidomide maintenance as per IMWG criteria * Patients who have already started or received multi-drug consolidation regimen post-transplant expect for lenalidomide maintenance * Diarrhea \> grade 1 in the absence of anti-diarrheals * Central nervous system involvement * Female patients who are lactating or have a positive serum pregnancy test during the screening period * History of allergy to mannitol * Major surgery within 14 days before enrollment * Radiotherapy within 14 days before randomization; if the involved field is small, 7 days will be considered a sufficient interval between treatment and administration of the ixazomib * Evidence of current uncontrolled cardiovascular conditions, including uncontrolled cardiac conditions such as hypertension, or cardiac arrhythmias, or New York Heart Association stage III and IV congestive heart failure, or unstable angina or myocardial infarction within the past 6 months * Rate-corrected QT interval of electrocardiograph (QTc) \> 470 msec on a 12-lead electrocardiogram (ECG) during screening * Uncontrolled diabetes * Acute infection requiring systemic anti-infectives, antivirals, or antifungals within two weeks prior to first dose * Systemic treatment, within 14 days before the first dose of ixazomib, with strong inhibitors of cytochrome P450 family 3, subfamily A, polypeptide 2 (CYP1A2) (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of cytochrome P450 family 3, subfamily A CYP3A (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort * Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive * Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol * Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent * Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing * Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection * Patient has \>= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period * Participation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With MRD Negativity | At 12 months | Rate of MRD negativity after 12 months of treatment with Ixazomib in combination with lenalidomide and dexamethasone compared to MRD negativity rate after 12 months of lenalidomide alone. For the majority of patients, where MRD positivity at screening will be determined by Multi-parameter Flow Cytometry (MFC), an improvement will be defined as a conversion from MRD-positive to MRD-negative disease by MFC. Additionally, in the fraction of patients with MRD-negative disease by MFC at screening, who were MRD-positive by Next Generation Sequencing (NGS), an improvement will be defined as a conversion from MRD-positive to MRD-negative disease by NGS |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response (Number of Participants With VGPR, CR, sCR) | At 6 months | Overall response was defined according to IMWG criteria as 1. very good partial response (VGPR) 2. complete response (CR) 3. stringent complete response (sCR) |
| Duration of MRD-negative Disease | every 28 days, up to 2 years | Duraion of MRD-negativie disease was defined as the duration from the date of MRD negative to the date of diseae progression or date of last clinical follow up. |
| Progression Free Survival | up to 2 years | Time to event will be estimated using the product-limit method of Kaplan and Meier. |
| Overall Survival | Up to 2 years | OS is the time from randomization date to death date. Participants who have not died will be censored on the last date they are known to be alive. |
| Number of Patients With Adverse Events | Up to 30 days post-treatment, **up to 2 years** | Graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORAndrzej Jakubowiak
University of Chicago
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 59.1 years |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants |
| Race (NIH/OMB) Black or African American | 4 Participants |
| Race (NIH/OMB) More than one race | 1 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 16 Participants |
| Sex: Female, Male Female | 8 Participants |
| Sex: Female, Male Male | 12 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 20 | 0 / 22 |
| other Total, other adverse events | 20 / 20 | 19 / 22 |
| serious Total, serious adverse events | 5 / 20 | 2 / 22 |
Outcome results
None listed